Neu auf wallstreet:online?
Jetzt registrieren | Login
x
Benutzername:

Passwort:

Angemeldet bleiben
Passwort vergessen?

CTIC und NOVARTIS...fette Partnerschaft und vile $$$$$$..hier gehts heute ab!!! - 500 Beiträge pro Seite

eröffnet am 18.09.06 12:15:38 von
Irishkiller

neuester Beitrag 10.10.06 14:38:23 von
pascal12
Beiträge: 50
ID: 1.082.749
Aufrufe heute: 0
Gesamt: 4.897


Beitrag schreiben Ansicht: 500 Beiträge pro Seite
Avatar
Irishkiller
schrieb am 18.09.06 12:15:38
Beitrag Nr. 1 (24.016.978)
die Top News!!!!:eek::eek::eek:

war ja abzusehen nach den ganzen Insider Käufen der letzten Tage.....;););)

Press Release Source: Cell Therapeutics, Inc.


Cell Therapeutics Inc. Announces Worldwide License and Co-Development Agreement for Development and Commercialization of XYOTAX(TM), an Investigational Agent for Treatment of Women with Non-small Cell Lung Cancer and Other Cancers
Monday September 18, 6:00 am ET
Deal Worth Up to $285 million Can Help Fuel Future Growth at CTI
SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced an exclusive worldwide licensing agreement with Novartis for the development and commercialization of XYOTAX(TM) (poliglumex paclitaxel), an investigational agent in Phase III for the treatment of non-small cell lung cancer (NSCLC) and other cancers.
ADVERTISEMENT


Total product registration and sales milestones for XYOTAX under the agreement could reach as much as $270 million. Novartis has also agreed to make a $15 million equity investment in CTI. CTI will have the option of co- detailing XYOTAX in the United States under the direction of Novartis, under an agreement to be entered into if CTI exercises the option. The closing of the transaction is subject to antitrust regulatory clearance and certain other closing conditions.

XYOTAX(TM) (Zi-o-taks) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, resulting in a new chemical entity. The investigational medicine is currently in phase III clinical trials to test whether single agent XYOTAX(TM) provides improved overall survival compared to paclitaxel in women with NSCLC and poor performance status.

The agreement also provides Novartis with an option to develop and commercialize pixantrone based on agreed terms. Pixantrone is an investigational agent designed to potentially increase anti-tumor activity and decrease the potential for cardiac toxicity associated with the currently marketed anthracyclines. If Novartis exercises its option on pixantrone under certain conditions, Novartis would pay CTI a $7.5M fee and up to $104M in registration and sales related milestones.

"This agreement brings the strength of one of the most innovative leaders in oncology to the development and commercialization of XYOTAX, an agent that could be demonstrated in ongoing trials to prolong survival in women with lung cancer and potentially become the first gender specific therapy for this disease," said James A. Bianco, M.D., President and CEO of CTI. "It also provides pixantrone with potential access to a market leader in blood related cancer therapeutics to fully maximize its commercial potential."

Bianco added: "This collaboration takes CTI one step closer to rebuilding its commercial presence in the United States and its goal of becoming a profitable cancer focused company. It also allows us to continue our growth through an acquisition strategy looking for other novel targeted agents to add to our development pipeline and into our future commercial infrastructure."

CTI had also announced in June that they have agreed on pathways for regulatory approvals for XYOTAX in recent meetings with the U.S. Food and Drug Administration (FDA) and the European Medicine Agency's Scientific Advice Working Party (SAWP). Lung cancer continues to be a major killer of men and women on both continents. In the United States, lung cancer is now the number one cancer killer of women.

The common stock to be issued to Novartis has not been registered under the Securities Act of 1933, as amended, or any state securities laws. The common stock may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and any applicable state laws. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of this common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About XYOTAX

XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplified administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.

Conference Call

A conference call will be held on September 18, 2006 at 8:30 am (ET) to discuss the agreement. The domestic call-in number is 1-800-240-7305 and the international number is 1-303-205-0033. The call will be webcast live and archived after the call for replay and may include forward-looking information.

This press release includes and the conference call may include forward- looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These forward looking statements include statements regarding the conditions to effectiveness of the agreements being satisfied, the achievement of any product registration and sales milestones under the agreement and the amount of any such milestones, the development and commercialization of XYOTAX and pixantrone and CTI's future operations and plans. The risks and uncertainties that could affect the achievement or amount of any product registration and sales milestones include risks associated with Novartis choosing to exercise its rights under the license agreement, the achievement of the product and sales milestones set forth in the license agreement and Novartis' ability to terminate the license agreement. The risks and uncertainties that could affect the development of XYOTAX and pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX and pixantrone in particular including, without limitation, the potential failure of XYOTAX to prove safe and effective for treatment of lung and ovarian cancers and pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling XYOTAX and pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.




--------------------------------------------------------------------------------
Avatar
Irishkiller
schrieb am 18.09.06 12:18:13
Beitrag Nr. 2 (24.017.020)
Antwort auf Beitrag Nr.: 24.016.978 von Irishkiller am 18.09.06 12:15:38
Avatar
Irishkiller
schrieb am 18.09.06 12:23:22
Beitrag Nr. 3 (24.017.087)
Cell Therapeutics, Novartis in agreement on Xyotax


LONDON (MarketWatch) -- Cell Therapeutics, Inc. (CTIC : Cell Therapeutics Inc
Last: 1.95+0.01+0.52%

4CTIC1.95, +0.01, +0.5%) has signed a licensing and co-development agreement with Novartis (NVS




NVS57.06, -0.05, -0.1%) for Xyotax, a lung-cancer drug. under the deal, Cell Therapeutics could receive up to $270 million depending on sales milestones. Novartis has also agreed to make a $15 million equity investment in Cell Therapeutics.
Avatar
Irishkiller
schrieb am 18.09.06 12:27:55
Beitrag Nr. 4 (24.017.125)
strong buy!!!!!;)
Avatar
Irishkiller
schrieb am 18.09.06 12:36:02
Beitrag Nr. 5 (24.017.274)
Antwort auf Beitrag Nr.: 24.017.087 von Irishkiller am 18.09.06 12:23:22Stuttgart auf 1,70 hochgetaxt,,,,

und an den anderen börsen werden zum Zeitpunkt keine bid/ask kurse gestellt.....

hihi...was das wohl zu bedeuten hat.....:lick:
Avatar
Qork
schrieb am 18.09.06 12:58:06
Beitrag Nr. 6 (24.017.571)
IN D vom Handel ausgesetzt!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Avatar
Irishkiller
schrieb am 18.09.06 13:44:21
Beitrag Nr. 7 (24.018.188)
bid in USA bei 2,20:eek::eek:.....sicher gleich noch weiter steigend.....


hehehe..wie weit wird das Teil heute laufen???


Wer wagt eine Prognose??
Avatar
Irishkiller
schrieb am 18.09.06 13:46:33
Beitrag Nr. 8 (24.018.232)
8.30 Uhr Conference Call,da gibt es sicher Details des Deals.....


Avatar
Irishkiller
schrieb am 18.09.06 13:47:21
Beitrag Nr. 9 (24.018.249)
Antwort auf Beitrag Nr.: 24.018.188 von Irishkiller am 18.09.06 13:44:21steigt weiter....2,22;)
Avatar
weilrob
schrieb am 18.09.06 14:36:28
Beitrag Nr. 10 (24.019.067)
Antwort auf Beitrag Nr.: 24.018.249 von Irishkiller am 18.09.06 13:47:212,52
Avatar
dv7950
schrieb am 18.09.06 14:40:48
Beitrag Nr. 11 (24.019.139)
WANN KAM DIE NEWS RAUS?
Avatar
DMKE
schrieb am 18.09.06 14:57:50
Beitrag Nr. 12 (24.019.364)
Antwort auf Beitrag Nr.: 24.019.139 von dv7950 am 18.09.06 14:40:48kann bitte jemand die nachricht kurz zusammen fassen auf deutsch ... ?

danke !
Avatar
Qork
schrieb am 18.09.06 15:05:21
Beitrag Nr. 13 (24.019.520)
Handel wieder aufgenommen und bin dabei.:D:D:D:D:D
Avatar
eidman
schrieb am 18.09.06 15:08:50
Beitrag Nr. 14 (24.019.591)
Die Schweizer Novartis hat mit den US-Amerikanern ein weltweites exklusives Lizenzabkommen zur Entwicklung und Vermarktung des Produktkandidaten Xyotax (poliglumex paclitaxel) geschlossen. Der Wirkstoff stecke derzeit in der Phase III der klinischen Entwicklung für nicht-kleinzelligen Lungenkrebs (NSCLC) und andere Krebsarten, teilte Cell Therapeutics mit. Für die Produktregistrierung und das Erreichen von Meilensteinen könnte Cell Zahlungen von bis zu 270 Millionen Dollar erhalten. Zudem habe sich Novartis bereit erklärt, 15 Millionen Dollar in das Aktienkapital von Cell zu investieren./fat/ck
Avatar
eidman
schrieb am 18.09.06 15:12:23
Beitrag Nr. 15 (24.019.663)
Geld: 1,76 1.500 Stk.
Brief: 1,90 1.500 Stk.
Taxierungszeitpunkt 18.09.2006 15:09:43 Uhr
Avatar
eidman
schrieb am 18.09.06 15:15:58
Beitrag Nr. 16 (24.019.726)
Geld: 1,73 1.000 Stk.
Brief: 1,86 3.000 Stk.
Taxierungszeitpunkt 18.09.2006 15:15:23 Uhr


Deutschland;)
Avatar
DMKE
schrieb am 18.09.06 15:24:30
Beitrag Nr. 17 (24.019.919)
Antwort auf Beitrag Nr.: 24.019.591 von eidman am 18.09.06 15:08:50DANKE !

das klingt natürlich super :D:D:D hier sollte in den nächsten tagen einiges an potenzial drin sein ... :D
Avatar
pascal12
schrieb am 18.09.06 15:27:22
Beitrag Nr. 18 (24.019.980)
warum geschieht in FFM nichts??? Ich habe auch orders aufgegeben, aber es gibt keine Kurse???
Avatar
Qork
schrieb am 18.09.06 15:29:05
Beitrag Nr. 19 (24.020.016)
Antwort auf Beitrag Nr.: 24.019.980 von pascal12 am 18.09.06 15:27:22Kauf in Stuttgart oder US
Avatar
pascal12
schrieb am 18.09.06 15:31:37
Beitrag Nr. 20 (24.020.075)
sind da nicht die Gebühren wesentlich höher?
In DE war in FFm immer der höchste Umsatz bisher...
Avatar
wpdirekt
schrieb am 18.09.06 15:33:22
Beitrag Nr. 21 (24.020.102)
RT Nasdaq
2,42:kiss:
Avatar
Qork
schrieb am 18.09.06 15:35:32
Beitrag Nr. 22 (24.020.150)
Antwort auf Beitrag Nr.: 24.020.075 von pascal12 am 18.09.06 15:31:37Deine Gebühren hättest Du jetzt schon wieder drin:D:D:D
Avatar
Irishkiller
schrieb am 18.09.06 15:38:22
Beitrag Nr. 23 (24.020.232)
wow....schon 3,5 millionen gehandelt...und nebenbei tageshoch bei 2,53!!!!;)

rock on!:)
Avatar
schappi64
schrieb am 18.09.06 15:49:39
Beitrag Nr. 24 (24.020.481)
du meinst 1,53euro.:):):)
Avatar
pascal12
schrieb am 18.09.06 15:53:14
Beitrag Nr. 25 (24.020.577)
was hats Euch so gekostet? ich habe jetzt in FFM für 1,88Euro bekommen (zum Glück hatte ich schon vorher Stücke zu 1,07)
Avatar
wallstreetcrash
schrieb am 18.09.06 17:12:35
Beitrag Nr. 26 (24.022.300)
Antwort auf Beitrag Nr.: 24.020.577 von pascal12 am 18.09.06 15:53:14..für diese Wahnsinnsnachricht hätte ich eigentlich auf noch mehr bums gehofft..;)
Naja , ist ja im Vorfeld schon schön gestiegen..
Vieleicht erreiche ich meinen einstandpreis von 2,8€ dieses Jahr noch:(:cry::cry:
Avatar
pascal12
schrieb am 18.09.06 17:22:07
Beitrag Nr. 27 (24.022.478)
vor ca 1 Monat, als die Testergebnisse herauskammen, sind sie mehr gestiegen. Heute haben sie schon viel wieder von den Gewinnen eingebüßt. aber bei 2,50USD hocken noch viele ehemalige Käufer - dass wird eine schwierige Marke. Aber wenn die Zulassung kommt fällt eh jede Marke:laugh:
Avatar
pascal12
schrieb am 18.09.06 17:24:19
Beitrag Nr. 28 (24.022.514)
in München bid - ask 1,55 zu 1,60 heißt, dass da bietet jemand Aktien für 1,60€ an oder was bedeutet dieses bid - ask immer?
Avatar
Irishkiller
schrieb am 18.09.06 23:14:53
Beitrag Nr. 29 (24.031.230)
Antwort auf Beitrag Nr.: 24.022.300 von wallstreetcrash am 18.09.06 17:12:35sehe ich genauso..hatte auch einen grösseren Anstieg erwartet!

Aber wie Du schreibst,die Aktie ist im Vorfeld schon beachtlich gestiegen,wahrscheinlich dahe einige Gewinnmitnahmen..

Umsätze heute phenomenal,auch das lässt auf weitere steigende Kurse hoffen!

Bin gespannt,wie es morgen weiter geht,hält der Uptrend an,bin ich weiterhin sehr sehr zuversichtlich.


Mein Einstiegskurs liegt auch höher,immerhin 5000 Stück zu 2,83 Euro,hoffe-und bin optimistisch-den auch recht bald wiederzusehen,,,,


Werde sicher auch weiter halten,ähnliches Szenario hatte ich mal bei Elan,auch viel zu füh verkauft,und dann an der Aussenlinie zugesehen,wie das Teil von 3 bis knapp 20 Dollar lief!!!


Meiner Meinung nach ist die heutige PR ein Indiz dafür,dass wir sehr wahrscheinlich im kommenden Jahr(Mitte??) die Zulassung für Xyotax sehen werden,steigende Kurse im Vorfeld sind zu erwarten,,,,

viel Glück allen!!!


Avatar
pascal12
schrieb am 19.09.06 08:18:02
Beitrag Nr. 30 (24.034.420)
Antwort auf Beitrag Nr.: 24.031.230 von Irishkiller am 18.09.06 23:14:53Der Aktionär meinte, die Zulassung für Europa wohl schon diesen Herbst und in den Staaten nächstes Jahr
Avatar
Irishkiller
schrieb am 19.09.06 09:42:43
Beitrag Nr. 31 (24.035.798)
Antwort auf Beitrag Nr.: 24.034.420 von pascal12 am 19.09.06 08:18:02stimmt,

ähnliches habe ich in irgendeinem US-Aktienforum auch gelesen....

dann könnte ja der Uptrend-alleine spekulierend auf diese News-weiterhin anhalten....

time will tell,,,
Avatar
Kamala20
schrieb am 19.09.06 10:07:56
Beitrag Nr. 32 (24.036.264)
yahoo board:

Next stop, interim pixantrone data Q1/07 and interim xyotax data Q2/07, with potential approval for xyotax by Q4/07 or (more likely, IMO) Q1/08.



noch ein weiter Weg vor uns......

Avatar
pascal12
schrieb am 19.09.06 10:21:00
Beitrag Nr. 33 (24.036.503)
ist dass eine offizielle Nachricht? Auf der Ctic-Homepage steht nichts davon
Avatar
Irishkiller
schrieb am 19.09.06 14:14:56
Beitrag Nr. 34 (24.040.835)
nein,

wie geschrieben aus dem Yahoo Message Board.....:)
Avatar
Irishkiller
schrieb am 19.09.06 14:15:52
Beitrag Nr. 35 (24.040.850)
aber das ist offiziell:::;););)


News:


Press Release Source: Cell Therapeutics, Inc.


Cell Therapeutics, Inc. to Present at UBS Global Life Sciences Conference
Tuesday September 19, 7:00 am ET



SEATTLE, Sept. 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) management will present at the UBS 2006 Global Life Sciences Conference on Wednesday, September 27 at 4:00 pm (ET).
The conference will be held September 25-28, 2006, at the Grant Hyatt Hotel in New York City. The presentation will be audio webcast live and available for replay approximately three hours after the presentation ends. The webcast can be accessed on the CTI web site at www.cticseattle.com.


UBS 2006 Global Life Sciences Conference
CTI Presentation: Wednesday, September 27
4:00 p.m. ET/1:00 p.m. PT/10:00 p.m. CET
Audio webcast at www.cticseattle.com



Avatar
Irishkiller
schrieb am 19.09.06 14:19:58
Beitrag Nr. 36 (24.040.947)
Antwort auf Beitrag Nr.: 24.040.850 von Irishkiller am 19.09.06 14:15:52und der daraus resultierende Anstieg des Aktienkurses auch.....


bid bei 2,15!Immerhin..gute 10% plus...


rock on!;)


Avatar
pascal12
schrieb am 19.09.06 14:22:04
Beitrag Nr. 37 (24.040.975)
wo und wie erfährt man den von einer eventuellen Zulassung durch die FDA? Oder wird man davon immer überrascht?
Avatar
pascal12
schrieb am 19.09.06 14:24:39
Beitrag Nr. 38 (24.041.025)
wieso steigt der Kurs nach Bekanntgabe, dass sie bei einer Präsentation dabei sind?
Avatar
Irishkiller
schrieb am 19.09.06 14:26:32
Beitrag Nr. 39 (24.041.055)
mehr News.....

Press Release Source: Cell Therapeutics, Inc.
Cell Therapeutics Inc. Announces Registered Offering of $40 Million in Common Stock
Tuesday September 19, 8:22 am ET


SEATTLE, Sept. 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced that it has agreed to sell approximately 23,121,387 shares of its common stock at a per share price of $1.73 per share in a registered offering. CTI has also granted the purchasing investors a 90-day option to purchase approximately an additional 5,780,346 shares at the same price per share.
ADVERTISEMENT


The offering is expected to close on or about September 21, 2006, subject to certain closing conditions.

Rodman & Renshaw, LLC acted as the lead placement agent and sole book runner on this transaction. Punk, Ziegel and Company acted as the co-placement agent.

A shelf registration statement relating to the common stock to be issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. The risks and uncertainties include the risk that the above described transaction will not close as a result of the failure to meet closing conditions, investors may breach or withdraw their commitment, and until closed there is no assurance that it will close or what the total amount may be, and other risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K and 8-K. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.




--------------------------------------------------------------------------------
Source: Cell Therapeutics, Inc.


Avatar
pascal12
schrieb am 19.09.06 14:32:33
Beitrag Nr. 40 (24.041.181)
was bedeutet den dieser Mist? Die Kurse rasen runter...
Avatar
Irishkiller
schrieb am 19.09.06 14:33:12
Beitrag Nr. 41 (24.041.158)
Antwort auf Beitrag Nr.: 24.041.055 von Irishkiller am 19.09.06 14:26:32...und daraus resultierende Abschläge.....shit...so schnell kann's gehen:(:(:(


1.95 0 (0.00) 0 1.78 (20) + 1.79 (100) 2,105,986
Avatar
Berta Roker
schrieb am 19.09.06 14:44:20
Beitrag Nr. 42 (24.041.438)
sowas ist für mich der allerletzte dreck

kaum gibts mal eine gute news, wird solcher schrott sofort abverkauft per plazierung an der börse und die aktienpresse sofort angeschmissen

strong sell

mir kommt das kotzen bei solchen werten :mad::mad:
Avatar
pascal12
schrieb am 19.09.06 14:48:54
Beitrag Nr. 43 (24.041.528)
aber das dürfte keine langfristige Auswirkung haben, oder?
Avatar
DMKE
schrieb am 19.09.06 15:23:41
Beitrag Nr. 44 (24.042.237)
Antwort auf Beitrag Nr.: 24.041.528 von pascal12 am 19.09.06 14:48:54so ein mist ... weg damit :cry::mad::mad::mad:
Avatar
Irishkiller
schrieb am 19.09.06 15:29:43
Beitrag Nr. 45 (24.042.374)
Antwort auf Beitrag Nr.: 24.042.237 von DMKE am 19.09.06 15:23:41locker bleiben.....gibt ja anscheinend auch genügend Käufer....


in einem Jahr lachen wir über die momentanen Kurse;)
Avatar
GiovanniTrappertoni
schrieb am 20.09.06 19:53:10
Beitrag Nr. 46 (24.068.586)
Abverkauf geht weiter



Avatar
pascal12
schrieb am 21.09.06 12:19:41
Beitrag Nr. 47 (24.080.165)
heute endet doch der zeitliche Rahmen für diese Verkaufsaktion.
Dann steht ab morgen Kursen von über 1,73$ nichts im Wege...
Avatar
mfierke
schrieb am 25.09.06 05:13:57
Beitrag Nr. 48 (24.178.719)
:rolleyes::rolleyes::rolleyes:
Avatar
Pitti72
schrieb am 26.09.06 20:09:19
Beitrag Nr. 49 (24.216.549)
Cell Therapeutics Inc. Completes Registered Offering of $40 Million in Common Stock
Tuesday September 26, 7:00 am ET


SEATTLE, Sept. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that it had completed the previously announced sale of 23,121,394 shares of its common stock at a per share price of $1.73 per share in a registered offering. CTI has also granted the purchasing investors a 90-day option to purchase an additional 5,780,352 shares at the same price per share.
ADVERTISEMENT


Rodman & Renshaw, LLC acted as the lead placement agent and sole book runner on this transaction. Punk, Ziegel and Company acted as the co-placement agent.

A shelf registration statement relating to the common stock issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering has been filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.




--------------------------------------------------------------------------------
Source: Cell Therapeutics, Inc.
Avatar
pascal12
schrieb am 10.10.06 14:38:23
Beitrag Nr. 50 (24.535.135)
endloch scheint sich wiedr was zu tun. NY vorbörslich 7% im Plus.
Aber es gibt keine Nachrichten?!?




Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.

Meistdiskutierte Aktien (24h)

WertpapierBeiträge
728
129
94
68
66
49
47
46
42
41